# Obinutuzumab Beta Combined With Low-dose Glucocorticoid in New-onset ANCA-Associated Glomerulonephritis

> **NCT07746180** · PHASE2 · RECRUITING · sponsor: **Chinese PLA General Hospital** · enrollment: 20 (estimated)

## Conditions studied

- ANCA-Associated Glomerulonephritis (AAGN)
- ANCA-Associated Vasculitis (AAV)

## Interventions

- **DRUG:** Obinutuzumab beta
- **DRUG:** Glucocorticoids

## Key facts

- **NCT ID:** NCT07746180
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-21
- **Primary completion:** 2028-10-30
- **Final completion:** 2029-03-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07746180

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07746180, "Obinutuzumab Beta Combined With Low-dose Glucocorticoid in New-onset ANCA-Associated Glomerulonephritis". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07746180. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*